The global market for chemotherapy-induced peripheral neuropathy is estimated to grow with a healthy CAGR of 5.1% from 2022 to 2030. The market will reach $1,521.9 million by 2030 from $967.7 million in 2021. Symptoms arising from peripheral nerve damage can be termed as peripheral neuropathy. The condition affects the movement of arms & legs and bowel & bladder. Cancer patients undergoing chemotherapy are susceptible to develop peripheral neuropathy, i.e., chemotherapy-induced peripheral neuropathy/CIPN. Chemo-drugs like oxaliplatin, docetaxel, vincristine, bortezomib etc. are associated with a higher frequency for CIPN. CIPN symptoms are usually worst in first three-five months, i.e., after the last chemotherapy dose. After this period, the symptoms usually lessen/disappear. However, in certain cases CIPN may be permanent.
Get a Free Sample Copy of this Report@ https://www.astuteanalytica.com/request-sample/chemotherapy-induced-peripheral-neuropathy-market
The global market for CIPN is being driven by increasing prevalence of cancer, rising R&D and clinical trials in the field, and growing awareness for the disease. As per the factsheet of 2021, published by American Cancer Society, 1.9 million new cancer cases and 608,570 cancer deaths were reported within US. Such high number of cancer cases increases the patient pool susceptible for CIPN.
Lidocaine (IV), cannabinoids, cryotherapy, acupuncture, exercise, and massage therapy are reported to effective against CIPN. Additionally, pharmaceutical companies like WEX Pharmaceuticals and MediciNova are developing possible drug candidates for CIPN treatment. However, lack of diagnostic methods and lack of any therapeutic treatment are the major restraining factors for the market growth.
Segment Overview
By Therapy
- Medications
- Surgery
- Transcutaneous electrical nerve stimulation
- Others
By Region
- The US
- The UK
- France
- Germany
- Spain
- Italy
- Japan
Key Takeaways
- Medications segment is the largest segment by therapy and occupies 55% of the market in 2021. The segment is projected to grow with the fastest CAGR of 5.45%
- Surgery segment is estimated to cross the mark of $150 million by 2025
- By region, North America held largest share of 42%, accounting for $2,834.8 million in 2021
- Asia Pacific is estimated to be the fastest growing region. The segment is estimated to grow with a CAGR of 5.7% during the forecast period
Value Addition
- The prevalence of CIPN varies by chemotherapeutic agent used, i.e., within a range from 19% to more than 85%. With the use of platinum-based medicines, taxanes, thalidomide and its analogues, and ixabepilone, ~70–100%, 11-87%, 20-60%, 60-65% patients are reported to have CIPN, respectively
- Germany has the highest CIPN incident population. There are 165,095 CIPN cases reported within Germany. Germany is followed by the UK. The UK had 120,624 CIPN cases. On the other hand, Spain had the smallest incident population (73,071 CIPN patients)
- Disease Background and Overview
- Sign and Symptoms
- Pathophysiology
- Risk Factors
- Diagnosis
- Competitive Intelligence Analysis for CIPN
- Country Wise-Epidemiology of Cancer Pain
- United States Epidemiology
- Prevalent cases of CIPN in the United States
- Gender-specific CIPN Prevalence
- Age-specific CIPN
- EU5 Epidemiology (Germany, France, Italy, Spain and the UK)
- Japan Epidemiology
- Current Treatment Practices
- Clinical Practice Guideline: Treatment of CIPN
- Patient Journey
- Marketed Drugs
- Olesoxime (TRO19622): MedImmune /Abbott Laboratories Inc.
- Product Description
- Regulatory Milestones
- Developmental Activities
- Pivotal Clinical Trials
- Olesoxime (TRO19622): MedImmune /Abbott Laboratories Inc.
- Calmangafodipir: Egetis Therapeutics /Solasia Pharma K.K.
- Pregabalin: Pfizer’s
- Emerging Drugs
- Tetrodotoxin (TTX): Wex Pharmaceuticals
- Product Description
- Clinical Development
- Clinical Trials Information
- Safety and Efficacy
- Product Profile
- Thrombomodulin alfa: Veloxis Pharmaceuticals
- Sodium selenite pentahydrate: Boryung Pharmaceutical Co., Ltd
- Memantine: Mendel AI
- Nicotinamide Riboside: ChromaDex, Inc.
- Tetrodotoxin (TTX): Wex Pharmaceuticals
Competitive Landscape
Orexo AB, MundiPharma International Ltd., Biodelivery Sciences International Inc., Hisamitsu Pharma Co., Teva Pharma Industries Ltd., CK life Science (WEX Pharma), Daiichi Sankyo Co., Pfizer Inc., Roche Holding AG, and others are some of the prominent players in the market.
It is estimated that four major players of the market occupy 35% of the market share.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.astuteanalytica.com/industry-report/chemotherapy-induced-peripheral-neuropathy-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact us:
Aamir Beg
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: www.astuteanalytica.com
Follow US: LinkedIn | Twitter